Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 484Carcinoma, Non-Small-Cell Lung 440Prostatic Neoplasms 292Lung Neoplasms 170Stomach Neoplasms 140Neoplasms 114Squamous Cell Carcinoma of Head and Neck 109Neoplasm Metastasis 97Head and Neck Neoplasms 96Esophageal Neoplasms 71Ovarian Neoplasms 57Pancreatic Neoplasms 42Urinary Bladder Neoplasms 39Sarcoma 39Nasopharyngeal Carcinoma 36Carcinoma, Squamous Cell 30Triple Negative Breast Neoplasms 28Carcinoma, Ovarian Epithelial 28Adenocarcinoma of Lung 27Adenocarcinoma 27Esophageal Squamous Cell Carcinoma 25Parkinson Disease 4, Autosomal Dominant Lewy Body 23Carcinoma, Transitional Cell 23Adenocarcinoma Of Esophagus 23Breast Neoplasms, Male 22Recurrence 21Unspecified Adult Solid Tumor, Protocol Specific 20Inflammatory Breast Neoplasms 20Fallopian Tube Neoplasms 20Melanoma 18

Interventions

palbociclib 1S 1 (combination) 1Docetaxel 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Cancer Recurrent × Docetaxel × Clear all
NCT02947061 2016-10-31

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
300 enrolled
Breast

Breast Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡